Novartis Institutes For Biomedical Research, Inc was Sangamo Therapeutics’s largest revenue line in fiscal 2022, bringing in $39.73M of $110.90M (36%).
| Counterparty Name | FY 2021 | FY 2022 |
|---|---|---|
| Novartis Institutes For Biomedical Research, Inc | $37.94M | $39.73M |
| Biogen Ma, Inc | $42.30M | $28.42M |
| Kite Pharma, Inc | $25.45M | $38.59M |
| Sanofi S.A | $3.11M | $3.26M |
| Sigma-Aldrich Corporation | $1.10M | $900.00K |
| Total | $109.91M | $110.90M |
Sangamo Therapeutics brought in $110.90M from its five revenue lines in fiscal 2022, the year ended December 31, 2022. That was up 0.9% from $109.91M in fiscal 2021. Novartis Institutes For Biomedical Research, Inc was the largest at $39.73M (35.8%), ahead of Kite Pharma, Inc at $38.59M (34.8%) and Biogen Ma, Inc at $28.42M (25.6%). The other two revenue lines brought in $4.16M combined.
Compared with fiscal 2021, Kite Pharma, Inc grew fastest, up 51.6% to $38.59M, while Biogen Ma, Inc fell the most, down 32.8% to $28.42M.
License was Sangamo Therapeutics’s largest product and service line in fiscal 2022, bringing in $58.85M of $110.00M (54%).
| Product and Service | FY 2016 | FY 2021 | FY 2022 |
|---|---|---|---|
| License | $54.20M | $58.85M | |
| License & Service | $29.98M | $32.02M | |
| Collaboration Agreements | — | — | |
| Research Services | $24.61M | $18.67M | |
| Research Grants | — | — | |
| Milestone Achievement | $23.00K | $457.00K | |
| Total | $108.81M | $110.00M |
Sangamo Therapeutics brought in $110.00M from its four product and service lines in fiscal 2022, the year ended December 31, 2022. That was up 1.1% from $108.81M in fiscal 2021. License was the largest at $58.85M (53.5%), ahead of License & Service at $32.02M (29.1%) and Research Services at $18.67M (17.0%). The remaining line, Milestone Achievement, brought in $457.00K.
Compared with fiscal 2021, License grew fastest, up 8.6% to $58.85M, while Research Services fell the most, down 24.1% to $18.67M.
Sangamo Therapeutics (SGMOQ) reports its revenue by counterparty name and by product and service. In fiscal 2022, Novartis Institutes For Biomedical Research, Inc was its largest revenue line, bringing in $39.73M (35.8% of the total), followed by Kite Pharma, Inc at $38.59M (34.8%).
Novartis Institutes For Biomedical Research, Inc was Sangamo Therapeutics' largest revenue line in fiscal 2022, bringing in $39.73M, or 35.8% of the $110.90M total across its five revenue lines.
License was Sangamo Therapeutics' largest product and service line in fiscal 2022, bringing in $58.85M, or 53.5% of the $110.00M total across its four product and service lines.
Among Sangamo Therapeutics' revenue lines that make up at least 2% of revenue, Kite Pharma, Inc grew fastest in fiscal 2022, up 51.6% from $25.45M to $38.59M.
Every figure comes from Sangamo Therapeutics' annual financial filings, as reported. Each line keeps the name Sangamo Therapeutics gives it, and years follow its fiscal calendar.
Sangamo Therapeutics' revenue by counterparty name goes back to fiscal 2021, with figures through fiscal 2022. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.